4202-Hem-301
Research payments
$818,770
Through program year 2025, $818,770 in research payments was reported against 4202-Hem-301, across 202 payments.
- Paid by (largest first)
- Novo Nordisk AS; Novo Nordisk Inc
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $336,722 | 102 |
| 2024 | Research | $480,448 | 98 |
| 2023 | Research | $1,600 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Fuad El Rassi Atlanta, GA Named on 17 payments
- Patrick Ellsworth Chapel Hill, NC Named on 15 payments
- Marilyn Telen Durham, NC Named on 15 payments
- Farzana Pashankar New Haven, CT Named on 8 payments
- Kenneth Rivlin New York, NY Named on 8 payments
- Zahra Pakbaz Orange, CA Named on 7 payments
- Darla Liles Greenville, NC Named on 7 payments
- Modupe Idowu Houston, TX Named on 6 payments
- Robert Irwin Tacoma, WA Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.